Martyna Wroblewska, Author at BaseLaunch

All Features

BaseLaunch Summer Get-Together 2023

We are very pleased to have had so many experts, partners, and friends joining our Summer Get-together this year! It was an incredible day filled…

Martyna Wroblewska04.08.2023

All Featured Portfolio news

Versameb strengthens its Board of Directors

Versameb, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD,…

Martyna Wroblewska12.07.2023

All Featured Portfolio news

Cimeio Therapeutics and Prime Medicine announce research collaboration

Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime…

Martyna Wroblewska22.06.2023

All Features

How Swiss life sciences startups can compete globally

How Swiss life sciences startups can compete globally In this biotech networking event, Johnson & Johnson Innovation shared their approach towards external innovation and their…

Martyna Wroblewska06.06.2023

All Features

Bridge Biotherapeutics’ partnering strategy and growth by external innovation

Bridge Biotherapeutics’ partnering strategy and growth by external innovation In this biotech networking event, two speakers from Bridge Biotherapeutics talked about the history of their…

Martyna Wroblewska25.05.2023

All Featured Portfolio news

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…

Martyna Wroblewska12.05.2023

All Featured Portfolio news

Phialogics closed a €600k pre-seed financing round with HTGF

Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…

Martyna Wroblewska21.04.2023

All Featured Portfolio news

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…

Martyna Wroblewska21.04.2023

All Portfolio news

BaseLaunch Portfolio has raised over half a billion dollars to date!

We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M! Just the last…

Martyna Wroblewska13.04.2023

All Portfolio news

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…

Martyna Wroblewska13.04.2023

Martyna Wroblewska

BaseLaunch Summer Get-Together 2023

Versameb strengthens its Board of Directors

Cimeio Therapeutics and Prime Medicine announce research collaboration

How Swiss life sciences startups can compete globally

Bridge Biotherapeutics’ partnering strategy and growth by external innovation

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics closed a €600k pre-seed financing round with HTGF

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

BaseLaunch Portfolio has raised over half a billion dollars to date!

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us